You may indeed be right that 3Q14 Sovaldi prescriptions may be fewer than for 2Q. In the big picture, however, it's Ledivaldi prescriptions that will blow the doors off, beginning with FDA approval in 4Q14 and launching in full next year.
Agree with Feurstein that GILD is likely to sell off for a brief time no matter the Sovaldi sales and overall revenues and profits. At least that's what happened after 1Q14 and the massive Sovaldi blowout.
Staying long and strong.
The noise from health insurers is their attempt to protect their short-term bottom lines. Sovaldi reduces overall healthcare costs especially for the sickest HepC cases, but it's an expense that is hitting the insurers now, rather than over a multi-year time frame as before.
As a shareholder in GILD and other biotechnology companies, but not in health insurers, I have no qualms about the former reaping the benefits of their breakthrough new medicines at the expense of the latter. The public as a whole will certainly side with GILD, which a near-term cure for a chronic infectious disease, and one with a relatively benign side effect profile.
I also have a problem with the talk of warehousing HepC patients based on the severity of their disease. Given that chronic HepC can cause long-term consequences like increased liver cancer, it may be most beneficial from a treatment perspective to cure the disease as soon as possible, even for those cases that aren't the sickest.
Why bother? In the Western world, Sovaldi is typically covered by Medical insurance.
Where did I hear about it? The paper describing the phase III clinical study was just published in Journal of the American Medical Association.
The states are covering the treatment costs for the same pool of HepC patients now eligible for Sovaldi. The only difference to their bottom line is that treating the chronic liver problems spreads their cost over a more protracted time frame than paying for a 12 week course of Sovaldi, and soon an 8 week course of Ledivaldi.
In fairness, her comment was focused on the small cap social media and biotech sectors, and aren't applicable to GILD. It's the Street that's throwing out the baby with the bathwater.
Scripts flattening out now, which should still lead to roughly $3 billion in 2Q Sovaldi sales. The game changer going forward will be the once-a-day Sovaldi/Ledipasvir pill.
Congratulations, your recent post on the Yahoo GILD message board has been awarded the 'least intelligent post of the year award' by the Darwin Society. Your award is in recognition that the claim that hepatitis C can be cured with a vitamin, when there are now available drug treatments that for the first time genuinely cure this chronic debilitating disease.
New to BIND and interested in the technology. Can someone explain to me why the nanoparticle targeting using prostate specific membrane antigen is being used to direct chemo-loaded particles to cancers other than prostate? How does this promote chemo delivery to lung and other non-prostate tumor types?
No, I don't agree. CELG has already won in court and had one of the patent challenges thrown out, and they hold additional issued patents suggesting their position is strong. Even should one of their patents be overturned, it would have to cover the Sovaldi composition of matter to be relevant and it would only result in a tiny single digit royalty licensing arrangement.
Lol, so liberals like to destroy companies? How did the economy do in the Clinton administration? In the GW Bush administration?
Political bashing is easy for the simple minded, but the truth is more complex.
Please find me more 'frauds' like this one. Sales this year will be double those of last year, the forward P/E is conservatively estimated at less than 11, the company has a broad array of drug candidates in various stages of clinical development, and the two-drug once-a-day all oral Hep C curative treatment will be approved by FDA later this year.
What does Obamacare have to do with the price of Sovaldi in the US?
Our free market system lets drug companies and the marketplace set drug prices. True for treatments for HepC, for cancer, for Gaucher's disease, etc.
Created with American tax dollars? It was created by Pharmasset, which cost GILD $11 billion to purchase. American tax dollars support the academic biomedical research enterprise, which provides the knowledge, tools, and technologies to foster the discovery of new drugs and diagnostics.
Frustration? If you think the stock is woefully undervalued (and I agree with this sentiment), then it's a fantastic buying opportunity. Back up your trucks!